323 related articles for article (PubMed ID: 8281479)
1. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
2. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
3. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
Varah N; Smith J; Baugh RF
Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
[TBL] [Abstract][Full Text] [Related]
4. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
[TBL] [Abstract][Full Text] [Related]
5. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
6. Clinical safety and cost of heparin titration using bedside activated clotting time.
Thomason T; Riegel B; Jessen D; Smith SC; Gocka I; Rich M
Am J Crit Care; 1993 Jan; 2(1):81-7. PubMed ID: 8353584
[TBL] [Abstract][Full Text] [Related]
7. Activated coagulation time in monitoring heparinized dogs.
Green RA
Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
9. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
Noureddine SN
Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
[TBL] [Abstract][Full Text] [Related]
10. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
11. Validation of a bedside activated clotting time test (Hemochron Jr II Signature) with low dose heparin therapy.
Racioppi L; Quinart A; Biais M; Nouette-Gaulain K; Revel P; Sztark F
Anaesthesia; 2009 Apr; 64(4):430-4. PubMed ID: 19317710
[TBL] [Abstract][Full Text] [Related]
12. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass.
Dauchot PJ; Berzina-Moettus L; Rabinovitch A; Ankeney JL
Anesth Analg; 1983 Aug; 62(8):710-9. PubMed ID: 6869857
[TBL] [Abstract][Full Text] [Related]
13. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
14. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques.
Carter AJ; Hicks K; Heldman AW; Resar JR; Laird JR; Coombs VJ; Brinker JA; Blumenthal RS
Cathet Cardiovasc Diagn; 1996 Sep; 39(1):97-102. PubMed ID: 8874958
[TBL] [Abstract][Full Text] [Related]
16. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
[TBL] [Abstract][Full Text] [Related]
17. [The use of activated clotting time (ACT) to optimize heparinization during coronary angioplasty. The nursing personnel of the Hemodynamics Laboratory].
Dellavalle A; Steffenino G; Ribichini F; Russo P; Conte L; Conte E; Uslenghi E
G Ital Cardiol; 1995 Apr; 25(4):445-51. PubMed ID: 7642051
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
[TBL] [Abstract][Full Text] [Related]
19. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
Cavusoglu E; Lakhani M; Marmur JD
J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
[TBL] [Abstract][Full Text] [Related]
20. Use of the activated partial thromboplastin time for heparin monitoring.
Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
